4:39 PM
 | 
Oct 21, 2013
 |  BC Extra  |  Company News

Angiochem advances ANG1005 for cancer

Angiochem Inc. (Montreal, Quebec) said it will continue to develop ANG1005 (formerly GRN1005) based on additional Phase II data showing the compound produced responses in breast cancer patients with brain metastases. Last year, Geron Corp....

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >